InvivoGen's product citations
InvivoGen’s products are frequently cited in peer-reviewed publications for a wide variety of applications and uses. Browse our product citations below.
Please note: By clicking on the product name, you can access via the ‘Citations’ tab all references of the product (click ‘load more’).
Citations search
You can search by ‘Product Name’ or ‘Year’.
| Product | Citation | Year | Journal | Authors | Page |
|---|---|---|---|---|---|
| QUANTI-Blue™ | Spatial organization of FcγR and TLR2/1 on phagosome membranes differentially... | 2021 | Sci Rep. | Li W. et al. | DOI: 10.1038/s41598-021-92910-9 |
| Zeocin® | Spatial organization of FcγR and TLR2/1 on phagosome membranes differentially... | 2021 | Sci Rep. | Li W. et al. | DOI: 10.1038/s41598-021-92910-9 |
| RAW-Blue™ Cells | Spatial organization of FcγR and TLR2/1 on phagosome membranes differentially... | 2021 | Sci Rep. | Li W. et al. | DOI: 10.1038/s41598-021-92910-9 |
| Pam3CSK4 Biotin | Spatial organization of FcγR and TLR2/1 on phagosome membranes differentially... | 2021 | Sci Rep. | Li W. et al. | DOI: 10.1038/s41598-021-92910-9 |
| Normocin® - Antimicrobial Reagent | Spatial organization of FcγR and TLR2/1 on phagosome membranes differentially... | 2021 | Sci Rep. | Li W. et al. | DOI: 10.1038/s41598-021-92910-9 |
| FSL-1 | Toll-like receptor 2 induces pathogenicity in Th17 cells and reveals a role f... | 2021 | Cell Rep. | Marks K.E. et al. | DOI: 10.1016/j.celrep.2021.109303 |
| Pam3CSK4 | Toll-like receptor 2 induces pathogenicity in Th17 cells and reveals a role f... | 2021 | Cell Rep. | Marks K.E. et al. | DOI: 10.1016/j.celrep.2021.109303 |
| ODN 1585 VacciGrade™ | Central Nervous System-Endogenous TLR7 and TLR9 Induce Different Immune Respo... | 2021 | Front Neurosci. | Storgaard Dieu R. et al. | DOI: 10.3389/fnins.2021.685645 |
| Imiquimod VacciGrade™ (R837) | Central Nervous System-Endogenous TLR7 and TLR9 Induce Different Immune Respo... | 2021 | Front Neurosci. | Storgaard Dieu R. et al. | DOI: 10.3389/fnins.2021.685645 |
| THP1-Blue™ NF-κB Cells | Anti-Inflammatory Potential of Simvastatin Loaded Nanoliposomes in 2D and 3D ... | 2021 | Nanomedicine | Rakshit M. et al. | DOI: 10.1016/j.nano.2021.102434 |
| Normocin® - Antimicrobial Reagent | Anti-Inflammatory Potential of Simvastatin Loaded Nanoliposomes in 2D and 3D ... | 2021 | Nanomedicine | Rakshit M. et al. | DOI: 10.1016/j.nano.2021.102434 |
| Normocin® - Antimicrobial Reagent | Targeted Chemotherapy of Glioblastoma Spheroids with an Iontronic Pump. | 2021 | Adv Mater Technol. | Waldherr L. et al. | DOI: 10.1002/admt.202001302 |
| Anti-CD20 (Rituximab biosimilar - IgG2 isotype) | Development of a Macrophage-Based ADCC Assay. | 2021 | Vaccines (Basel). | Uccellini M.B. et al. | DOI: 10.3390/vaccines9060660 |
| Recombinant anti-CD20 antibody (Rituximab biosimilar - IgG1NQ isotype) | Development of a Macrophage-Based ADCC Assay. | 2021 | Vaccines (Basel). | Uccellini M.B. et al. | DOI: 10.3390/vaccines9060660 |
| Anti-HER2 (Trastuzumab biosimilar - IgG1 isotype) | Development of a Macrophage-Based ADCC Assay. | 2021 | Vaccines (Basel). | Uccellini M.B. et al. | DOI: 10.3390/vaccines9060660 |
| Anti-CD20 (Rituximab biosimilar - mIgG1 isotype) | Development of a Macrophage-Based ADCC Assay. | 2021 | Vaccines (Basel). | Uccellini M.B. et al. | DOI: 10.3390/vaccines9060660 |
| Anti-CD20 (Rituximab biosimilar - mIgG2a isotype) | Development of a Macrophage-Based ADCC Assay. | 2021 | Vaccines (Basel). | Uccellini M.B. et al. | DOI: 10.3390/vaccines9060660 |
| Anti-CD20 (Rituximab biosimilar - IgG3 isotype) | Development of a Macrophage-Based ADCC Assay. | 2021 | Vaccines (Basel). | Uccellini M.B. et al. | DOI: 10.3390/vaccines9060660 |
| Anti-CD20 (Rituximab biosimilar - IgG1 isotype) | Development of a Macrophage-Based ADCC Assay. | 2021 | Vaccines (Basel). | Uccellini M.B. et al. | DOI: 10.3390/vaccines9060660 |
| 3p-hpRNA - RIG-I agonist | Mechanism of Nucleic Acid Sensing in Retinal Pigment Epithelium (RPE): RIG-I ... | 2021 | J Immunol Res. | Schustak J. et al. | DOI: 10.1155/2021/9975628 |